The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

Major bleeding was low overall, but the findings align with other large datasets showing greater risk with rivaroxaban.

A new, generic, non-steroidal anti-inflammatory drug (NSAID) is now available for managing osteoarthritis (OA) pain in horses ...

Researchers from Cologne, Bochum, Padova and Angers have discovered a novel connection between mitochondrial function, ...

A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!

Nerandomilast worked better than a placebo to preserve lung function in adults with progressive pulmonary fibrosis in a Phase 3 study.

Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...

Tokyo, Japan and Cambridge, UK, 14 February 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the ...